Biomarkers of Parkinson’s disease: 20 years later
Despite intensive effort, biomarker research for the detection of prodromal stage, diagnosis and progression of Parkinson’s disease (PD) falls short of expectations. This article reviews the attempts in the last 20 years to find a biomarker, addresses challenges along the biomarker search and suggests the steps that should be taken to overcome these challenges. Although several biomarkers are currently available, none of them is specific enough for diagnosis, prediction of future PD or disease progression. The main reason for the failure finding a strong biomarker seems to be drastic heterogeneity of PD, which exhibits itself in all domains; from the clinic to pathophysiology or genetics. The diversity in patient selection, assessment methods or outcomes in biomarker studies also limit the interpretation and generalizability of the data. In search of a reliable biomarker, consideration of novel approaches encompassing individual demographic, clinical, genetic, epigenetic and environmental differences, employment of strategies enabling marker combinations, designing multicenter studies with compatible assessment methods, integration of data from preclinical domains and utilization of novel technology-based assessments are necessary.
KeywordsParkinson’s disease Biomarker Prodromal Parkinson’s disease
- Braak H, Del Tredici K, Rüb U et al Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211Google Scholar
- Parkinson J (1817) An essay on the shaking palsy. Whittingham and Rowland Sherwood, Neely and Jones, LondonGoogle Scholar
- Smith AR, Smith RG, Burrage J et al (2019) A cross-brain regions study of ANK1 DNA methylation in different neurodegenerative diseases. Neurobiol Aging 74:70–76. https://doi.org/10.1016/j.neurobiolaging.2018.09.024 CrossRefGoogle Scholar